About Ultragenyx Pharmaceutical Inc.
https://www.ultragenyx.comUltragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally.
CEO
Emil D. Kakkis
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 146
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:10.13M
Value:$243.89M
FMR LLC
Shares:7.28M
Value:$175.31M
BLACKROCK, INC.
Shares:6.43M
Value:$154.66M
Summary
Showing Top 3 of 382
About Ultragenyx Pharmaceutical Inc.
https://www.ultragenyx.comUltragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $159.93M ▼ | $302.83M ▲ | $-180.41M ▼ | -112.81% ▼ | $-1.81 ▼ | $-156.79M ▼ |
| Q2-2025 | $166.5M ▲ | $251.38M ▼ | $-114.95M ▲ | -69.04% ▲ | $-1.17 ▲ | $-91.34M ▲ |
| Q1-2025 | $139.29M ▼ | $253.57M ▼ | $-151.08M ▼ | -108.46% ▼ | $-1.57 ▼ | $-126.44M ▼ |
| Q4-2024 | $164.88M ▲ | $270.26M ▲ | $-133.38M ▲ | -80.9% ▲ | $-1.39 ▲ | $-108.8M ▼ |
| Q3-2024 | $139.49M | $250.46M | $-133.52M | -95.71% | $-1.4 | $-108.74M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $425.25M ▼ | $1.19B ▼ | $1.17B ▲ | $9.16M ▼ |
| Q2-2025 | $477.38M ▼ | $1.31B ▼ | $1.15B ▼ | $151.29M ▲ |
| Q1-2025 | $494.44M ▼ | $1.31B ▼ | $1.16B ▼ | $144.25M ▼ |
| Q4-2024 | $610.02M ▼ | $1.5B ▼ | $1.24B ▲ | $255.3M ▼ |
| Q3-2024 | $621.61M | $1.54B | $1.18B | $346.83M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-180.41M ▼ | $-91.42M ▲ | $117.18M ▲ | $2K ▼ | $26.05M ▼ | $-92.7M ▲ |
| Q2-2025 | $-114.95M ▲ | $-108.27M ▲ | $71.17M ▼ | $83.65M ▲ | $49.47M ▲ | $-95.73M ▲ |
| Q1-2025 | $-151.08M ▼ | $-166.47M ▼ | $119.89M ▲ | $157K ▼ | $-44.98M ▼ | $-182.8M ▼ |
| Q4-2024 | $-133.38M ▲ | $-79.5M ▼ | $102.73M ▲ | $3.19M ▼ | $23.95M ▲ | $-80.16M ▼ |
| Q3-2024 | $-133.52M | $-67M | $-275.5M | $11.17M | $-330.05M | $-68.61M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Product | $70.00M ▲ | $90.00M ▲ | $80.00M ▼ | $90.00M ▲ |
 Royalty | $90.00M ▲ | $50.00M ▼ | $90.00M ▲ | $60.00M ▼ |
Revenue by Geography
| Region | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Asia Pacific | $0 ▲ | $0 ▲ | $0 ▲ | $10.00M ▲ |
 EMEA | $0 ▲ | $0 ▲ | $30.00M ▲ | $30.00M ▲ |
 Europe | $30.00M ▲ | $20.00M ▼ | $0 ▼ | $0 ▲ |
 Latin America | $20.00M ▲ | $50.00M ▲ | $30.00M ▼ | $40.00M ▲ |
 North America | $120.00M ▲ | $60.00M ▼ | $100.00M ▲ | $80.00M ▼ |
CEO
Emil D. Kakkis
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 146
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:10.13M
Value:$243.89M
FMR LLC
Shares:7.28M
Value:$175.31M
BLACKROCK, INC.
Shares:6.43M
Value:$154.66M
Summary
Showing Top 3 of 382